Skip to main content
FinSpry Logo
FinSpry
BMRN logo
BMRN
(NASDAQ)
BioMarin Pharmaceutical Inc.
$55.50-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

BioMarin Pharmaceutical (BMRN) Stock Price & Financial Analysis

BioMarin Pharmaceutical Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$54.54 - $56.55
52-Week High$69.87
52-Week Low$50.76
Open$56.42
Volume2.31M
Average Volume (3M)2.31M
Market Cap10.96B
Shares Outstanding197.39M
P/E Ratio (TTM)32.38
Forward P/E39.62
Price to Sales (P/S)3.51
Price to Book (P/B)1.86
EV/EBITDA18.55
Revenue (TTM)3.22B
Net Income (TTM)348.90M
Free Cash Flow (TTM)719.39M
EPS (TTM)$1.77
Profit Margin10.83%
Operating Margin16.56%
Return on Equity (ROE)5.73%
Debt to Equity0.11
50-Day MA$58.40
200-Day MA$56.53
52-Week Change-15.75%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About BioMarin Pharmaceutical

What is the current stock price for BMRN?

As of the latest trading session, BMRN stock trades at $55.50. The 52-week range is $50.76–$69.87, with a day range of $54.54–$56.55.

What is the P/E ratio for BMRN?

BioMarin Pharmaceutical's trailing P/E ratio is 32.4, meaning investors pay $32.4 for every $1 of annual earnings. The forward P/E is 39.6, reflecting analyst expectations for future earnings. BioMarin Pharmaceutical operates in the Healthcare sector.

Does BMRN pay dividends?

BioMarin Pharmaceutical does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for BMRN?

Based on 21 analysts, the consensus for BMRN is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of BMRN?

BioMarin Pharmaceutical's market capitalization is $10.96B, classifying it as a large-cap company. BioMarin Pharmaceutical operates in the Healthcare sector within the Biotechnology industry.